Indian Pharma Industry Growth May Hit Drug Pricing and Regulatory Overhang Roadblocks

Syringe with glass vials and medications pills drug

A report covered in Express Pharma predicts that growth in the Indian pharma market may be capped just shy of last year’s numbers. In its prediction, the report notes this may occur in response to pricing negotiations, ongoing supply chain disruptions, inflation, and regulatory pressure. However, the report is overall neutral-to-positive for the industry

According to Express Pharma, “ICRA maintains its stable outlook on the pharma industry, led by expectations of continued steady revenue growth and comfortable profit margins. It expects the sample set’s return indicators, capital structure and coverage indicators to remain comfortable, despite higher capex and R&D expenses, which are likely to be partly funded through strong internal accrual generation and available surplus liquidity, the statement added.”

To read more, click here.

(Source: Express Pharma, January 9^th, 2022)